Janiel M. Cragun

University of Arizona — United States

Medicine · Health Sciences

23h-index3.7kcitations54works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(27), Endometrial and Cervical Cancer Treatments(10), Cancer Genomics and Diagnostics(10), Gene expression and cancer classification(6), Endometriosis Research and Treatment(6)

Publications54 total

miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk
Scientific Reports·2024· 2 citedOpen Access
Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Functional Biomarkers Associated with Ovarian Cancer Risk
2024Open Access
Data from Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
2023Open Access
Supplementary Data from Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
2023Open Access
Data from Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
2023Open Access
Supplementary Data from Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
2023Open Access
Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL
Clinical Cancer Research·2019
Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations
Journal of the Advanced Practitioner in Oncology·2019· 4 citedOpen Access
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
Journal of Clinical Oncology·2019· 22 cited
The utility of patient reported data in a gynecologic oncology clinic
Gynecologic Oncology Research and Practice·2018· 5 citedOpen Access
Incidence of hypersensitivity reactions to carboplatin or paclitaxel in patients with ovarian, Fallopian tube, or primary peritoneal cancer with or without <i>BRCA1</i> or <i>BRCA2</i> mutations.
Journal of Clinical Oncology·2018· 2 cited
Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL
Clinical Cancer Research·2017
Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial
European Journal of Cancer·2016· 1 cited
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
The Lancet Oncology·2016· 1.2k citedOpen Access
MRI of ovarian torsion: Correlation of imaging features with the presence of perifollicular hemorrhage and ovarian viability
European Journal of Radiology·2016· 28 cited
Using Quality of Life Data to Redesign Interventions and Allocate Resources toward Treatment and Survivorship in a Gynecologic Oncology Program
Gynecologic Oncology·2016
Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).
Journal of Clinical Oncology·2016· 34 cited
Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.
Journal of Clinical Oncology·2016· 14 cited
Assessment of the Role of Intraoperative Frozen Section in Guiding Surgical Staging for Endometrial Cancer
International Journal of Gynecological Cancer·2016· 28 cited
Review Article The role of the fallopian tube in ovarian serous carcinogenesis: biologic mechanisms and clinical impacts
2015
page 1 of 3Next →

Frequent Co-authors

Setsuko K. Chambers(15), Amit M. Oza(11), Andrew Berchuck(10), Holly K. Dressman(9), Johnathan M. Lancaster(9), Wenxin Zheng(9), Robyn Sayer(8), Joseph R. Nevins(8), Gottfried E. Konecny(7), Yiying Wang(7), Kevin Lin(6), Heidi Giordano(6), Robert L. Coleman(6), David M. O’Malley(6), James D. Brenton(6), Iain A. McNeish(6), Anil Potti(6), Gina Chan(6), Hope M. Cottrill(6), Jeffrey R. Marks(6)